CNR2 and early-onset autosomal dominant Alzheimer disease: MDA7 (NTRX-07) is a CB2-preferring agonist developed by Naguib et al. and NeuroTherapia [18,19,20]; it progressed into Phase I trials for the indications of neuropathic pain (NCT04375436) and Alzheimer’s disease (NCT06194552), and according to press releases, this compound is progressing into Phase II studies for Alzheimer’s disease.